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Abstract  
Background Sarcomas are rare mesenchymal malignancies whose pathogenesis is poorly 
understood; both environmental and genetic risk factors could contribute to their etiology.  
Methods and results We performed whole-exome sequencing (WES) in a familial aggregation of 3 
individuals affected with soft-tissue sarcoma (STS) without TP53 mutation (Li-Fraumeni-Like, LFL) and 
found a shared pathogenic mutation in CDKN2A tumor suppressor gene. We searched for individuals 
with sarcoma among 474 melanoma-prone families with a CDKN2A-/+ genotype and for CDKN2A 
mutations in 190 TP53-negative LFL families where the index case was a sarcoma. Including the initial 
family, 8 independent sarcoma cases carried a germline mutation in the CDKN2A/p16INK4A gene. In 
5/7 formalin-fixed paraffin-embedded (FFPE) sarcomas, heterozygosity was lost at germline CDKN2A 
mutations sites demonstrating complete loss of function. As sarcomas are rare in CDKN2A/p16INK4A 
carriers, we searched in constitutional WES of 9 carriers for potential modifying rare variants and 
identified three in platelet-derived growth factor receptor (PDGFRA) gene. Molecular modeling 
showed that two never-described variants could impact the PDGFRA extracellular domain structure.  
Conclusion Germline mutations in CDKN2A/P16INK4A, a gene known to predispose to hereditary 
melanoma, pancreatic cancer and tobacco-related cancers accounts also for a subset of hereditary 
sarcoma. In addition, we identified PDGFRA as a candidate modifier gene.  
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SHORT REPORT  
Sarcomas are a complex group of rare malignant tumors derived from cells that originate from the 
mesenchyma. These tumors, which can affect both bone and soft tissue, include more than 50 
different subtypes. The annual incidence of soft tissue sarcomas (STS) is around 5 new cases per 
100 000 population, whereas it is 0.8 for bone sarcomas, in Caucasians. 1 They account for nearly 
20% of all pediatric solid malignant cancers, but less than 1% of all adult solid malignant cancers.2 
The pathogenesis of most sarcomas is still poorly understood and both environmental and genetic 
risk factor could contribute to their etiology. The main environmental factors are carcinogens, 
viruses, and ionizing radiation, particularly radiation therapy received for a first cancer.3 The risk of 
sarcoma is enhanced in several hereditary cancer syndromes, including Li-Fraumeni syndrome (LFS), 
a rare, dominant Mendelian cancer syndrome linked to TP53 mutations but also possibly to POT1 
mutations.4 5 Beyond these syndromes, there may be other complex heritable predispositions as well 
as others, not yet identified.6  
The potential for intrafamily exome-sequencing approach to identify additional cancer 
susceptibility genes has been demonstrated. Therefore, we conducted germline whole exome 
sequencing (WES) in 2 affected members of a three sarcoma-cases family (Patients I-2 and II-1, family 
7389, Table 1, figure 1A). We performed data mining applying the classical filtering strategies 
provided in Ingenuity Variant Analysis (IVA) software (Qiagen).7 With very stringent frequency 
filtering (MAF) <0.001%, using a Biological Context of sarcoma, three germline variants shared by 
both sarcoma-affected relatives (uncle and nephew), were identified in CDKN2A, PDGFRA and SKA3 
genes. Because of the loss of function mutation detected in CDKN2A and the well known role of 
CDKN2A in somatic sarcomagenesis, both in humans and mice, we focused first on this gene. 8 
CDKN2A is a known tumor suppressor gene and the first familial melanoma gene identified; it 
encodes two distinct proteins, p16INK4A and p14ARF, which both function in cell cycle regulation.9 We 
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confirmed the germline splice mutation (c.151-2A>G) with Sanger sequencing, and also in DNA 
extracted from formalin-fixed, paraffin-embedded (FFPE) tumoral tissue from the 3d case, deceased 
patient I-1 (figure S2A). We had previously identified this specific mutation in three independent, 
melanoma-prone families. Transcript analysis was performed for a proband, indicating that CDKN2A 
exon 2 had been skipped in both p16INK4A and p14ARF transcripts, creating putative frameshifts (figure 
S3). 
Next, we performed Sanger sequencing of CDKN2A for germline mutations in full collection A 
(190 unrelated families with suspected LFS or Li-Fraumeni like, LFL, whose index case was a sarcoma 
without detectable TP53 germline mutation). We identified a second carrier of a CDKN2A/P16INK4A 
germline mutation (p.Ile49Ser), a patient diagnosed with a pleomorphic liposarcoma at age 32 years 
whose brother died of osteosarcoma at age 24 years (Family 18998, Table 1, figure S1A & S2B). 
To explore further the potential connection between CDKN2A germline mutations and 
sarcoma, we reviewed the phenotypes in our collection of 296 melanoma-prone French families with 
CDKN2A/P16INK4A germline mutations (collection B; mutations were partially described previously10) 
and found 8 kindreds that contained at least one member with sarcoma. Among them, 5 probands 
with sarcoma carried the pathogenic familial CDKN2A/P16INK4A germline mutation (Table 1, families 
14288, 14291, 2225, 15118 and 14289, figure S1B) and three families had incomplete data (two 
untested index cases; one unconfirmed STS; figure S4A and C; material and methods). Overall, among 
the 296 families, the difference in sarcoma incidence between CDKN2A mutation carriers (5/593; 
0.84%; 95% confidence interval: 0.3%-2%) and non-carriers (1/298; 0.34%; 95%CI 0.02%-2.16%) did 
not reach statistical significance (p-value =0.67; &ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚ). Considering the yearly incidence 
in Caucasians of 5.8 per 100,000 1 and the mean follow-up duration in collection B of 46 years, the 
probability of observing at least 5 sarcomas in the 593 CDKN2A carriers population was 0,02 
(assuming a binomial distribution). In the 298 CDKN2A WT populations, the mean follow-up was 39 
years and the probability of observing at least 1 sarcoma was 49%.  
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Next, we searched for biological arguments. As loss of heterozygosity (LOH) is considered in 
ƚƵŵŽƌ ?Ɛ ďŝŽůŽŐǇ ĂƐ Ă ƐƚƌŽŶŐindicator to the causative role of a tumor suppressor, we performed 
Sanger sequencing in seven FFPE sarcoma blocs available from French patients. We identified LOH at 
the CDKN2A germline mutation site in 5/7 samples (Table 1; figure S2). These LOHs demonstrate the 
occurrence of a second genetic hit on CDKN2A and, therefore, complete loss of p16INK4A function in 5 
sarcomas, in accordance with the driver role of CDKN2A tumor suppressor gene in sarcomagenesis8.   
Finally, we interrogated the GenoMEL database containing 178 CDKN2A+ melanoma-prone 
families (collection C), after removal of 60 French families already included in collection B. We 
identified three additional independent CDKN2A mutation carriers affected with a sarcoma. One 
family was from Australia and carried a CDKN2A/p16INK4A p.Leu32Pro germline mutation (Family 
20473, Table 1, figure S1C). The second family was from the UK (21 kb deletion targeting 
CDKN2A/p14ARF exon 1b)(data not shown), and the third family was from the Netherlands but the 
initial diagnosis of fibrosarcoma case was revised to melanoma and therefore, was excluded.  
Overall, in collections A, B, and C, ascertained for Li-Fraumeni (A) or multiple cases of 
melanoma and/or pancreatic cancer (B and C), we identified eight independent families in which at 
least a CDKN2A/P16INK4A mutation carrier, had a sarcoma (Table 1). Therefore, based on probabilistic 
and biological arguments, CDKN2A/P16INK4A germline mutations can be strongly suspected to 
increase sarcoma risk. Interestingly, in the literature, two sarcoma cases in CDKN2A /P16INK4A 
mutation carriers were identified in families with melanoma/pancreatic cancer and very recently  
germline CDKN2A mutations were identified in two independent patients presenting with Li-
Fraumeni syndrome.11 12 In addition to the well known role of CDKN2A in somatic sarcomagenesis, 
other observations in animals suggested a germline effect.8 First, in a mouse model, deletion of the 
Cdkn2a locus could substitute for mutations in Trp53 to generate soft-tissue sarcomas.13 Second, in a 
naturally occurring, canine breed-specific histiocytic sarcoma, a genome-wide association study 
(GWAS) identified a haplotype near CDKN2A.14 In conclusion to our work and published data, 
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germline mutations in CDKN2A/P16INK4A, a gene known to predispose to hereditary melanoma, 
pancreatic cancer and tobacco-related cancers, accounts also for a subset of hereditary sarcoma.9 
As melanoma risk in CDKN2A mutation carriers is clearly associated with MC1R frequent 
alleles acting as modifiers, 15 we formulated the hypothesis that the very low frequency of sarcoma 
cases observed in CDKN2A/P16INK4A positive melanoma-prone families could be explained by rare 
modifiers alleles. In a model of oligogenic inheritance, it is challenging to identify rare germline 
variants that act in synergy to initiate cancer and GWAS are unable to identify rare disease-
predisposing variants.16 Candidate pathogenic variants for sarcoma risk in ATM, ATR, BRCA2 and 
ERCC2 genes were identified recently in a large sarcoma case control study, as well as POT1 variants 
in cardiac angiosarcoma , but other genes not yet identified could also play a role .5 6 To explore this 
hypothesis, we considered the two additional germline variants identified in PDGFRA and SKA3 genes 
in the WES data ŽĨƉĂƚŝĞŶƚ ?Ɛ/-2 and II-1, both sarcoma-affected (initial Family 7389).  In SKA3 gene, 
an insertion of 2T was supposed to have occurred in a stretch of 12 T but was unconfirmed by Sanger 
sequencing (figure S5). The platelet-derived growth factor receptor alpha gene (PDGFRA) harbored a 
germline missense mutation, c.335T>G, p.Leu112Arg, located in the extracellular receptor domain 
and predicted deleterious by 2 computational methods (GVGD and SIFT). This mutation was verified 
by Sanger sequencing and was also found in DNA extracted from FFPE-sarcoma tissue from the third 
family member, patient I-1, therefore being present in the 3 sarcoma-affected patients (Family 7389, 
Figure 1A & S7A). 
Next, we performed additional WES analyses in blood-extracted DNA from 7 probands 
affected with sarcoma that carried germline CDKN2A mutations (14288-II.1, 14289-I.1, 2225-II.1, 
14291-II.1 and 15118-II.1 in collection B; family 20473-I.4 in collection C; and 18998-II.1 in collection 
A). Subsequently, we data mined the WES available for a total of 9 CDKN2A/P16INK4A carriers affected 
with sarcoma, including 2 relatives. We applied the classical filtering strategies provided in IVA 
software (Qiagen) (figure S6).7 For variant frequency, we defined rare variants as those with a minor 
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allele frequency (MAF) <0.5%.16 The outcome of our filtering strategy was the selection of 82 variants 
spanning 76 genes. Among previously published sarcoma susceptibility genes, we found no 
mutations in TP53, ATR, BRCA2 and ERCC2.6 We found a c.8584+1G>A putative splice site mutation in 
ATM gene in patient 7389-I.2, but this variant was absent in the sarcoma affected relative, II.1. We 
also found, in patient 14291-II.1, a POT1 c.1127A>G, p.Gln376Arg missense variant, present at a 
frequency of 0.07% in Eur-Am ESP, and predicted deleterious by 4 prediction methods (SIFT, 
MutationTaster, Polyphen 2 and Condel). This variant was also present in the unaffected mother. 
More interestingly, we detected 2 other germline missense mutations (verified by Sanger 
sequencing, figure S7B & C) located in the extracellular receptor domain of the platelet-derived 
growth factor receptor alpha gene (PDGFRA), including one absent in public databases. The PDGFRA 
missense variant c.227A>G, p.Asn76Ser, predicted deleterious by 4 computational methods (GVGD, 
SIFT, Mutation Taster and Polyphen 2) was not present in unaffected mother that carried the 
CDKN2A p.Gly101Trp mutation (Family 14291, figure S1B). In the sarcoma-proband I-4 of family 
20473 (figure S1C), we identified another germline PDGFRA variant, c.1388C>G, p.Thr463Ser, 
described with an allelic frequency of 0.02%, and predicted deleterious by 2 computational methods 
(Mutation Taster and Condel). Co-segregation analysis was not informative (figure S1C). 
dŚĞW'&Zɲ ?ĐŽŵƉŽƐĞĚŽĨĞǆƚƌĂĐĞůůƵůĂƌ ? ƚƌĂŶƐ-membrane, and intracellular domains (figure 
1C) is activated by the binding of its ligand, which induces dimerization, followed by kinase domain 
activation.17 Germline oncogenic gain-of-function mutations in PDGFRA cause familial 
gastrointestinal stromal tumors (GIST) associated with other tumors.18 19 Accordingly, the variants 
described above were not oncogenic in classical cell transformation assays (data not shown). 
Nevertheless, these variants could favor sarcomagenesis by interfering with various PDGFRA 
molecular functions, either canonical or not.20 To study the impact of PDGFRA germline variants on 
the 3D receptor structure, we performed molecular modeling of 3 PDGFRA missense variants 
identified in CDKN2A carriers with sarcoma, the two variants absent from public databases, 
p.Asn76Ser (N76S), p.Leu112Arg (L112R), and the rare variant, p.Thr463Ser (T463S) (ESP Eur. Am. 
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0.02%). We added as a control, a frequent SNP, p.Ser478Pro (S478P) described with an allelic 
frequency of 10.26% (ESP Eur. Am.) and predicted neutral by 5 computational methods (GVGD, SIFT, 
Mutation Taster, Polyphen 2 and Condel), identified in patient 14288-II.1 and 14289-I.1 (figure S7D). 
ƐƚŚĞW'&ZɲƐŝŐŶĂůŝŶŐĐŽŵƉůĞǆŚĂƐƌĞŵĂŝŶĞĚƵŶĐŚĂƌĂĐƚĞƌŝǌĞĚĂƚƚŚĞƐƚƌƵĐƚƵƌĂůůĞǀĞů ? we modeled 
two extracellular immunoglobulin (Ig)-like domains (D1 and D5; figure 1C) containing these variants 
by homology with related domains. Structurally, all these domains feature fiǀĞƚŽĞŝŐŚƚɴ-strands that 
form two ɴ-sheets (Ăɴ-sandwich). Figure 1C illustrates how the variants N76S and L112R affect the 
ƐƚƌƵĐƚƵƌĞŽĨ ? ? /ŶƉĂƌƚŝĐƵůĂƌ ?E ? ?^ƉƌŽŵŽƚĞĚ ůĂƌŐĞƌɴ-ƐƚƌĂŶĚƐ ĨŽůĚ  ?ɴ ?ĂŶĚɴ ? ?ƉƌŝŽƌĂŶĚĂĨƚĞƌ ƚŚĞ
ŵƵƚĂƚŝŽŶƐŝƚĞ ?ĐŽŶƚƌŝďƵƚŝŶŐƚŽƐƚĂďŝůŝǌĂƚŝŽŶŽĨĂƉĞƌĨĞĐƚĂŶƚŝƉĂƌĂůůĞůɴ-ƐŚĞĞƚ ?ĐŽŶƐƚŝƚƵƚĞĚǁŝƚŚɴ ? ? ɴ ? ?
ĂŶĚ ɴ ? ƐƚƌĂŶĚƐ ĂŶĚ ŵĂŝŶƚĂŝŶĞĚ ďǇ Ă ƌĞŐƵůĂƌ ? ƐƚĂďůĞ ,-bond network that contrasted with the 
fluctuating network in the native protein. Moreover, this variant promoted destabilization of two 
ƐŵĂůůɴ-ƐƚƌĂŶĚƐ ?ɴ ?ĂŶĚɴ ? ?ƚŚĂƚǁĞƌĞƉƌĞƐĞŶƚŝŶƚŚĞŶĂƚŝǀĞƉƌotein. Variant > ? ? ?ZŝŶĚƵĐĞĚɴ-strand 
 ?ɴ ? ? ĨŽƌŵĂƚŝŽŶ ŝŶ ƉůĂĐĞ ŽĨ ƚŚĞ ƌĂŶĚŽŵ ĐŽŝůrather ŽďƐĞƌǀĞĚ ŝŶ ƚŚĞ ŶĂƚŝǀĞ ƉƌŽƚĞŝŶ ĂŶĚ ŝŶĐƌĞĂƐĞĚ ɴ-
ĨŽůĚŝŶŐŝŶƐĞŐŵĞŶƚƐŵŽƌĞĚŝƐƚĂŶƚĨƌŽŵƚŚĞŵƵƚĂƚŝŽŶƉŽŝŶƚ ?ɴƐƚƌĂŶĚƐɴ ? ?ɴ ? ?ĂŶĚɴ ? ? ?KƵƌĂŶĂůǇƐŝƐŽĨ
the impact of T463S and S478P variants in the D5 domain suggested only a slight increase in residual 
flexibility, but all its structural features were well-preserved with respect to the native protein. It 
ƐŚŽƵůĚ ďĞ ŶŽƚĞĚ ƚŚĂƚ Ă ĐŽŵƉƌĞŚĞŶƐŝǀĞ ĐŚĂƌĂĐƚĞƌŝǌĂƚŝŽŶ ŽĨ W'&Zɲ variants located in the 
extracellular domains may require detailed analysis of the full-length protein structure in the native 
and mutated states. 
Overall, our data identified PDGFRA as a new sarcoma candidate modifier gene. 
Unfortunately, PDGFRA was not included in the 72 genes panel studied in the recent study of 1162 
patients with sarcoma.6 PDGFRɲ belongs to the large family of membrane RTKs and play primary 
roles in mesenchymal tissue development. Recent whole-genome or whole-exome analyses have 
revealed numerous somatic mutations localized in the RTK-III extracellular domain which could have 
transforming potential, based on their structural and physicochemical effects on the receptor.21 
These mutations in PDGFRA extracellular domains could affect non-canonical RTK functions. Upon 
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ligand activation, RTKs are internalized and translocated into endosomal compartments for signaling. 
20 Overall, our genetic and molecular modeling results suggested that PDGFRA germline variants that 
affect the extracellular domain could play a role in sarcomagenesis, but the functional mechanism 
remains unknown.  
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Table 1: CDKN2A/P16INK4A germline mutations identified in eight families with members affected by sarcoma and candidate modifiers 
aAll subjects provided written informed consent for participation in these oncogenetic research studies which were approved by local research ethics committees. 
Collection (A) comprised 190 families with suspected Li-Fraumeni syndrome that included at least one member with sarcoma. Collection (B) comprised 300 melanoma-
prone French families CDKN2A/p16INK4A+ . Collection (C) comprised 250 CDKN2A/p16INK4A+ melanoma-prone families from the international GenoMEL database. 
bClinical context: LS, liposarcoma; AS, angiosarcoma; STS, soft-tissue sarcoma; OS, osteosarcoma; UCS, uterine carcinosarcoma; FS, fibrosarcoma; SVS, synovialosarcoma, 
MM, cutaneous melanoma; ages (y) at diagnosis appears in parentheses.  
cCDKN2A/P16INK4A exons 1alpha, 2, and 3 were sequenced by Sanger method based on transcript NM_000077.4  to screen for mutations in collections A, B, and C. None 
were present in public controls databases such as 1000 genomes or ExAC. 
dLOH analyses were performed by Sanger sequencing at germline CDKN2A mutations  sites in DNA extracted from sarcoma FFPE samples; NA, not analyzed
Collectionsa 
Family 
ID 
Patient 
ID 
Cases 
Clinical 
contextb 
P16 
exon 
p16INK4A mutationc 
p14ARF AA 
change 
Sarcoma LOH 
at 
CDKN2A/P16d 
Melanoma/ pancreatic 
cancer reports 
P16INK4A Loss of 
function 
PDGFRA 
variants 
Other candidate 
modifiers5 6 
A 7389 I-1 
I-2 
II-1 
LS (57) 
 AS (67) 
 STS (33) 
IVS 1 
IVS 1 
IVS 1 
c.151-2A>G 
c.151-2A>G 
c.151-2A>G 
c.194-2A>G 
c.194-2A>G 
c.194-2A>G 
No 
Yes 
Yes 
Yes  
(unpublished data) 
Splice p.Leu112Arg 
p.Leu112Arg 
p.Leu112Arg 
None 
ATM c.8584+1G>A 
ND   
A 1899
8 
II-1 
II-2 
LS (33) 
OS (24) 
 ?ɲ c.146T>G, p.Ile49Ser 
ND 
NA 
 
NA 
NA 
Yes  
(Holland E., 1999, 
Begg CB., 2005) 
Yes  
(Lal G., 2000) 
None 
None 
 
None 
None 
 
B 1428
8 
II-1 OS (16) 2 c.194T>C, 
p.Leu65Pro 
p.Ala79Ala Yes Yes 
(Landi MT., 2004) 
Yes 
(Landi MT., 2004) 
None 
 
None 
 
B 2225 II-1 UCS (43) 2 c.225_243del, 
p.Ala76fs 
 
p.Arg90fs Yes Yes 
(Gruis N., 1995) 
ND None 
 
None 
 
B 1428
9 
I-1 FS (69) 2 c.301G>T, 
p.Gly101Trp 
p.Arg115L
eu 
Yes Yes 
(Kannengiesser C., 
2009, Miller PJ., 2011) 
Yes 
(Ranade K., 1995, 
Kannengiesser C., 
2009) 
None 
 
None 
 
B 1429
1 
II-1 OS (13)+ 
MM 
(26,27) 
2 
 
c.301G>T, 
p.Gly101Trp 
p.Arg115L
eu 
NA   p.Asn76Ser POT1 
p.Gln376Arg 
B 1511
8 
II-1 SVS (57) 2 c.301G>T, 
p.Gly101Trp 
p.Arg115L
eu 
No   None None 
C 2047
3 
I-4 
I-2 
OS (7)+ 
8MM 
RMS (25) + 
MM (36) 
 ?ɲ c.95T>C, p.Leu32Pro 
ND 
NA 
 
NA Yes 
(Walker GJ., 1995, 
Goldstein A., 2007) 
Yes  
(McKenzie HA., 
2010) 
p.Thr463Ser 
ND 
 
None 
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Figures legends 
Figure 1. Whole exome sequencing in a 3-sarcoma cases family without TP53 germline mutation: 
identification of CDKN2A and PDGFRA germline mutations, co-segregating with sarcomas 
A, Pedigree of the Li-Fraumeni-like family. Cancer diagnosis and age at onset is indicated for affected 
members; hatched circles/squares indicate sarcoma: AGS, angiosarcoma; LPS, liposarcoma; STS, 
soft-tissue sarcoma. Genotypes of CDKN2A and PDGFRA for all samples available for testing are 
shown. Patients with WES data are indicated with a black star.  
B, WES germline SNV filtering and interpretation, for 2 patients of Family 7389. We used Ingenuity 
Variant Analysis software (v.2.1.20130711, IVA, Qiagen) and predetermined filters (see 
Bioinformatics analysis, supplementary on line). Starting with 307 690 variants spanning 17 673 
genes, successive filters lead to 3 variants spanning 3 genes (CDKN2A, PDGFRA and SKA3).  
C, Structural properties of PDGFRɲ wild-type and variants. (Upper row) the PDGFRɲ protein has a 
modular structure composed of five Ig-like domains (D1, D2, D3, D4, and D5), a trans-membrane 
domain (TMD), and a cytoplasmic region. The cytoplasmic region consists of a regulatory 
juxtamembrane region (JMR) and a catalytic kinase domain, with a N-lobe and a C-lobe, which 
harbors a kinase insert domain (KID). (Lower row) The X-ray analysis structures are represented as 
ribbon diagrams, based on the KIT structural data. D1 and D5 are denoted as ovals. (Middle row) 
schematic representations of D1 and D5 topologies. (Bottom figures) superimposed conformations of 
wild-type PDGFRɲ (blue) and PDGFRɲ germline variants (pink), obtained from molecular dynamics 
(MD) simulations. Representative conformations were selected by RMSDs clustering and are 
presented as ribbon diagrams. 
